Event

Kisaco Pharma & Biotech Litigation North America 2025

Fish & Richardson Principals Gwilym Attwell, Martina Hufnal, and Douglas McCann will speak at Kisaco Pharma & Biotech Patent Litigation North America on November 18. In addition, Principal Megan Chacon will serve as co-chair of the event.

Fish is proud to serve as a platinum partner of Kisaco Pharma & Biotech Patent Litigation North America 2025, which gathers U.S. life sciences intellectual property leaders to define, shape, and create successful patent litigation strategies. Session details are below.

Preliminary Injunction Practice Across the Life Science Patent Sector | Douglas McCann

Preliminary injunctions can be critical tools in high-stakes life sciences patent litigation, offering early relief to protect market share and prevent irreparable harm. This session will explore evolving legal standards, jurisdictional differences, and strategic considerations when seeking or defending against injunctive relief in the pharma and biotech space.

  • Discuss jurisdictional nuances and success rates for preliminary injunctions in the U.S., Asia, and UPC.
  • Determine strategic timing and evidentiary requirements: What do courts need to see?

Global Skinny Label Strategies and Case Law Within the U.S. and Farther Afield | Martina Hufnal

Skinny label litigation remains a critical flashpoint in the ongoing battle between branded and generic drug manufacturers. This session will explore the evolving legal landscape in the U.S. It will also examine international developments, with comparative insights from Europe and other major jurisdictions, helping you anticipate how global case law and regulatory dynamics may affect your patent enforcement or defense strategy.

  • Discuss key Hatch-Waxman cases and recent appellate decisions that are reshaping the boundaries of induced infringement and carve-out strategies:
    • Amarin v. Hikma (Fed. Cir. 2024): Examine how the Federal Circuit revived Amarin’s induced infringement claim over Hikma’s carved-out label, highlighting the role of press releases, product websites, and labeling content in shaping off-label use liability — even outside the Hatch-Waxman framework.
  • Understand the role of the Supreme Court and the impact of legal certainty on branded and generic pharmaceutical strategies.
  • Compare the skinny label position in the U.S. with case law and strategies in Canada, Europe, and Asia.

Roundtable: Alternatives to IPRs in the Life Sciences | Gwilym Attwell

For more information, or to register, click here.